[1]尹 虹,王豪浩,马继伟.贝前列素钠联合前列地尔对血液透析患者肾功能及血清全段甲状旁腺素、白细胞介素-13、白细胞介素-18水平的影响[J].陕西医学杂志,2023,52(10):1411-1414.[doi:DOI:10.3969/j.issn.1000-7377.2023.10.029]
　YIN Hong,WANG Haohao,MA Jiwei.Effects of Beraprost Sodium Combined with Alprostadil on Renal Function and Serum iPTH,IL-13,IL-18 Levels in Hemodialysis Patients[J].,2023,52(10):1411-1414.[doi:DOI:10.3969/j.issn.1000-7377.2023.10.029]
点击复制

贝前列素钠联合前列地尔对血液透析患者肾功能及血清全段甲状旁腺素、白细胞介素-13、白细胞介素-18水平的影响
分享到：

《陕西医学杂志》[ISSN:1000-7377/CN:61-1281/TN]

卷:
52
期数:
2023年10期
页码:
1411-1414
栏目:
药物与临床
出版日期:
2023-10-05

文章信息/Info

Title:
Effects of Beraprost Sodium Combined with Alprostadil on Renal Function and Serum iPTH,IL-13,IL-18 Levels in Hemodialysis Patients
作者:
尹 虹; 王豪浩; 马继伟
(河南中医药大学第一附属医院血液透析科,河南 郑州 450052)
Author(s):
YIN Hong; WANG Haohao; MA Jiwei
(Department of Hemodialysis,the First Affiliated Hospital of Henan University of Traditional Chinese Medicine,Zhengzhou 450052,China)
关键词:
前列地尔;  贝前列素钠;  血液透析;  慢性肾衰竭;  残余肾功能;  炎性因子
Keywords:
Prostaglandin;  Beraprost sodium;  Hemodialysis;  Chronic renal failure;  Residual renal function;  Inflammatory factors
分类号:
R 692.5
DOI:
DOI:10.3969/j.issn.1000-7377.2023.10.029
文献标志码:
A
摘要:
目的:探讨贝前列素钠联合前列地尔对血液透析患者肾功能及血清全段甲状旁腺素(iPTH)、白细胞介素-13(IL-13)、白细胞介素-18(IL-18)水平的影响。方法:选择156例行血液透析的CRF患者为研究对象,以随机数字表法将患者分为对照组(贝前列素钠片治疗)78例,观察组(贝前列素钠+前列地尔治疗)78例,并评价两组患者临床疗效,比较两组患者治疗前后血清肌酐(Scr)、血尿素氮(BUN)、24 h尿蛋白定量(24 hUP)、全段甲状旁腺素(iPTH)水平及血浆纤维蛋白原(Fib)、部分凝血活酶时间(aPTT)、凝血酶原时间(PT)、D-二聚体(D-D)水平。测定肾动脉血流动力学参数收缩期峰值流速(VS)、舒张末期流速(VD)和阻力指数(RI)值及血清中白细胞介素-13(IL-13)、白细胞介素-18(IL-18)水平。记录两组不良反应情况。结果:观察组总有效率为93.59%高于对照组的83.33%,差异有统计学意义(P<0.05)。治疗后,观察组血清Scr、BUN、iPTH水平及24 hUP低于对照组,eGFR较对照组提高,差异有统计学意义(均P<0.05)。观察组凝血功能、肾脏血流状态优于对照组,差异有统计学意义(均P<0.05)。观察组血清IL-13、IL-18水平均低于对照组,差异有统计学意义(均P<0.05)。观察组不良反应发生率10.26%,对照组不良反应发生率6.41%,比较差异无统计学意义(P>0.05)。结论:贝前列素钠联合前列地尔用于血液透析治疗中疗效显著,可以明显改善患者残余肾功能,降低iPTH、IL-13、IL-18水平,安全性较高。
Abstract:
Objective:To investigate the effects of combination of betaglandin sodium and prostaglandin on renal function and serum levels of whole parathyroid hormone(iPTH),interleukin-13(IL-13),and interleukin-18(IL-18)in hemodialysis patients.Methods:A total of 156 patients with CRF who received hemodialysis were selected as the research objects.The patients were randomly divided into the control group(treated with beprost sodium tablets)of 78 cases,and the observation group(treated with beprost sodium+prostaglandin)of 78 cases.The clinical efficacy of the two groups was evaluated.The serum creatinine(Scr),blood Blood urea nitrogen(BUN),24-hour urine protein quantification(24 hUP)Whole parathyroid hormone(iPTH)level and plasma fibrinogen(Fib),partial thromboplastin time(aPTT),Prothrombin time(PT),D-dimer(D-D)level.Measure the peak systolic velocity(VS),end diastolic velocity(VD),and resistance index(RI)values of renal artery hemodynamic parameters,as well as serum levels of interleukin-13(IL-13)and interleukin-18(IL-18).Record the adverse reactions in both groups.Results:The total effective rate of 93.59% in the observation group was higher than 83.33% in the control group(P<0.05).Compared with the control group,the serum levels of Scr,BUN,iPTH,and 24-hour UP in the observation group decreased,while eGFR decreased(all P<0.05).The improvement of coagulation function and renal blood flow status in the observation group was better than that in the control group(all P<0.05).After treatment,compared with the control group,the serum levels of IL-13 and IL-18 in the observation group decreased(all P<0.05).The incidence of adverse reactions was 10.26% in the observation group and 6.41% in the control group.Conclusion:The combination of betaglandin sodium and alprostadil has a significant therapeutic effect in hemodialysis treatment,which can significantly improve residual renal function in patients,reduce levels of iPTH,IL-13,and IL-18,and have high safety.

参考文献/References:

[1] Ito S,Manabe E,Dai Y,et al.Juzentaihoto improves adenine-induced chronic renal failure in BALB/c mice via suppression of renal fibrosis and inflammation[J].J Pharmacol Sci,2022,148(1):172-178.
[2] Elander J,Kapadi R,Coyne E,et al.Using patient feedback to adapt intervention materials based on acceptance and commitment therapy for people receiving renal dialysis[J].BMC Urol,2021,21(1):157.
[3] 郭云星,孙晓丹,彭彦平.不同血液净化方式在维持性血液透析患者不宁腿综合征治疗中的运用[J].陕西中医,2021,42(1):30-31.
[4] 姚向飞,刘 华,蔡 东,等.铁蛋白、钙、磷、甲状旁腺激素水平与维持性血液透析患者预后关系研究[J].陕西医学杂志,2023,52(3):297-300,304.
[5] Alexandrou ME,Loutradis C,Schoina M,et al.Ambulatory blood pressure profile and blood pressure variability in peritoneal dialysis compared with hemodialysis and chronic kidney disease patients[J].Hypertens Res,2020,43(9):903-913.
[6] 徐 维,袁立英,喻海燕.前列地尔联合肾康注射液对维持性血液透析老年患者微炎症状态的影响[J].中国老年学杂志,2021,41(19):4308-4311.
[7] 唐 荣,张 帆.氯沙坦钾联合贝前列素钠治疗对减少腹透液蛋白质丢失的作用[J].国际泌尿系统杂志,2023,43(1):147-149.
[8] 王海燕.慢性肾脏病及透析的临床实践指南Ⅱ[M].北京:人民卫生出版社,2005:7-8.
[9] 魏 华,王佳丽,杨玉霞.百令胶囊对慢性肾衰竭腹膜透析患者营养状况及微炎症状态的影响[J].陕西中医,2019,14(6):764-766.
[10] Murea M,Patel A,Highland BR,et al.Twice-weekly hemodialysis with adjuvant pharmacotherapy and transition to thrice-weekly hemodialysis:A pilot study[J].Am J Kidney Dis,2022,80(2):227-240.
[11] Elander J,Kapadi R,Coyne E,et al.Using patient feedback to adapt intervention materials based on acceptance and commitment therapy for people receiving renal dialysis[J].BMC Urol,2021,21(1):157.
[12] Fadel FI,Yamamah GAN,Hasanin RM,et al.Hearing assessment in Egyptian children with chronic renal failure on regular hemodialysis and renal transplantation children[J].Ther Apher Dial,2022,26(5):960-968.
[13] 崔利娜,付艳芹,辛雅萍,等.贝前列素钠联合前列地尔治疗老年早期糖尿病肾病患者的临床研究[J].中国临床药理学杂志,2020,36(22):3616-3620.
[14] 宋彩霞,晏 婷,晏珍元,等.贝前列素钠联合尿毒清改善血液透析患者残存肾功能的疗效观察[J].实用医学杂志,2022,38(4):494-497.
[15] 黄 振,蒋 婕.前列地尔联合左卡尼汀对糖尿病肾病血液透析患者营养指标、肾功能及血清炎症指标的影响[J].中国煤炭工业医学杂志,2019,22(3):245-249.
[16] 李子源,刘 云,谭荣韶,等.维持性血液透析患者微量元素与微炎症状态的相关性分析[J].中国血液净化,2022,21(7):492-496.
[17] 李红帅,徐 菲,秦雪娟,等.黄葵胶囊联合氢氯噻嗪治疗慢性肾小球肾炎的临床研究[J].现代药物与临床,2023,38(2):401-404.
[18] Wang S,Chen F,Yang S,et al.Interleukin-18[J].Int Heart J,2018,59(4):786-790.
[19] 梁美珍,林 捷,徐日明.芪地肾康汤联合前列地尔在糖尿病肾病治疗中的应用及对血清sICAM-1、尿CTGF水平的影响研究[J].中华中医药学刊,2022,40(4):203-206.
[20] 顾 晶,张 辉.高通量血液透析联合前列地尔治疗慢性肾衰竭的临床效果[J].实用临床医药杂志,2019,23(1):85-88,92.

相似文献/References:

[1]李 明,门 敏△,王丽萍,等.瑞舒伐他汀联合前列地尔治疗早期糖尿病肾病疗效研究*[J].陕西医学杂志,2019,(9):1223.
　LI Ming,MEN Min,WANG Liping,et al.Efficacy of rosuvastatin combined with alprostadil in the 〖JZ〗treatment of early diabetic nephropathy[J].,2019,(10):1223.

备注/Memo

备注/Memo:
基金项目:河南省中医药科学研究专项课题(2018ZY1001)
更新日期/Last Update: 2023-10-07